No products in the cart.
Pre-made Foravirumab benchmark antibody ( Whole mAb, anti-RV Antigenic Site III therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-221
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Foravirumab biosimilar, Whole Mab: Anti-RV Antigenic Site III therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Foravirumab is a monoclonal antibody for the prophylaxis of rabies. It is under development by Sanofi/Crucell.
| Products Name (INN Index) | Pre-Made Foravirumab biosimilar, Whole Mab: Anti-RV Antigenic Site III therapeutic antibody |
|---|---|
| INN Name | Foravirumab |
| Target | RV Antigenic Site III |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2008 |
| Year Recommended | 2009 |
| Companies | Crucell,Sanofi Pasteur |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Rabies |
| Development Tech | Human Phage Display |
| Previous Name | NA |
| Gm Offical Target Name | RV Antigenic Site III |
| Package |
Previous slide
Next slide
